Surging Ryoncil® Revenues: A Remarkable 69% Q2 Increase
Mesoblast reported a sharp step-up in commercial momentum for Ryoncil, its FDA-approved mesenchymal stromal cell therapy for pediatric steroid‑refractory...
Jon Napitupulu
Rani Soars With Oversubscribed $60.3M Private Placement
Rani Therapeutics has raised approximately $60.3 million in an oversubscribed private placement, selling Class A common stock and pre-funded...
Rani Therapeutics Soars with $1B Chugai Drug Collaboration
Rani Therapeutics has signed a collaboration and license agreement with Chugai Pharmaceutical to develop and commercialize an oral version...
XORTX Acquires Renal Anti-Fibrotic Program from Vectus
XORTX Therapeutics has signed a binding term sheet to acquire Vectus Biosystems’ renal anti-fibrotic program, anchored by the novel...
i-mab to Rebrand as Novabridge, Eyes Hong Kong IPO
I-Mab is pivoting to a new operating model and identity, unveiling plans to rebrand as NovaBridge Biosciences, pursue a...
Iovance Biotherapeutics Reports Inducement Grants for New Hires
Iovance Biotherapeutics has granted inducement stock options covering 62,790 shares to nine new non-executive employees, effective October 16, 2025....
Ryoncil® Revenues Surge a Startling 69% in Second Quarter
Mesoblast reported a sharp commercial acceleration for Ryoncil, its FDA‑approved mesenchymal stromal cell therapy for pediatric steroid‑refractory acute graft-versus-host...
Praxis Sees Positive Phase 3 Results for Essential Tremor
Praxis Precision Medicines reported positive topline results from two Phase 3 studies in its Essential3 program for ulixacaltamide in...
Agios to Host Q3 2025 Financial Results Call on Oct 30
Agios Pharmaceuticals will report third-quarter 2025 financial results and business highlights on October 30 via webcast, signaling a near-term...
BPGBio Reveals Phase 2 Data for Glioblastoma Drug BPM31510
BPGbio will present two posters at ESMO 2025 on its mitochondrial-targeting candidate BPM31510 in glioblastoma, alongside confirmation that the...